Denali Therapeutics Inc. DNLI Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Denali Therapeutics Inc.’s reported figures.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s free cash flow?
- Denali Therapeutics Inc. (DNLI) reported free cash flow of -$133.67M in Q1 2026.
- How has Denali Therapeutics Inc.'s free cash flow changed year-over-year?
- Denali Therapeutics Inc.'s free cash flow increased by 2.1% year-over-year, from -$136.55M to -$133.67M.
- What is the long-term trend for Denali Therapeutics Inc.'s free cash flow?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s free cash flow has grown at a 17.7% compound annual growth rate (CAGR), from -$219.89M to -$422.1M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.